Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
Efficacy and Safety of JAK Inhibitors in Patients With Alopecia Areata: a Single-center, Real-world Study
Second Affiliated Hospital, School of Medicine, Zhejiang University
150 participants
Jul 29, 2024
OBSERVATIONAL
Conditions
Summary
The introduction of Janus Kinase inhibitors (JAKi) seems to revolutionize the field of alopecia areata (AA) therapeutics. However, the ideal JAKi is not yet settled and the real-world data are still missing. To provide evidence about effectiveness and safety of different JAKi including tofacitinib, baricitinib, ritlecitinib，abrocitinib, upadacitinib and ifidancitinib in real-world settings and describe baseline disease characteristics and patients profiles that are considered good candidates for JAKi in the daily practice. Furthermore, we intended to investigate the efficacy and safety of JAK Inhibitors in patients With AA, as well as to provide clinical evidence for the clinicians and patients when they formulate individualized treatment plans.
Eligibility
Inclusion Criteria3
- Patients with alopecia areata between 2 to 18 years old
- Patients diagnosed with alopecia areata according to AA guideline
- AA Patients treated with JAKi including tofacitinib, baricitinib, ritlecitinib，abrocitinib, upadacitinib and ifidancitinib for more than 3 months
Exclusion Criteria5
- Patients had previously received hair implants
- Other alopecia
- Other diseases may induce alopecia including psoriasis, lichen planus, et al.
- Unable to estimate SALT score at baseline or at follow-up
- Patients are participating in other clinical trials
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
In the real-world settings, patients with AA treated with tofacitinib.
In the real-world settings, patients with AA treated with Baricitinib.
In the real-world settings, patients with AA treated with Ruxolitinib.
In the real-world settings, patients with AA treated with Upadacitinib.
In the real-world settings, patients with AA treated with Abrocitinib.
In the real-world settings, patients with AA treated with Ritlecitinib.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06573593